GlassScriptPhysician profile
Adam H Levy
NPI 1851504989
$44,087.33
in general payments reported to CMS, 2019-2025
42 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,970 · 2020: $534 · 2021: $3,530 · 2022: $7,370 · 2023: $6,897 · 2024: $20K · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $4,416 · Travel and Lodging: $1,131 · Education: $16.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,120.00 |
| Food and Beverage | $4,415.78 |
| Travel and Lodging | $1,130.81 |
| Education | $16.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17,860.21 | 2023-2025 | Voquezna |
| Abbvie INC. | $17,514.79 | 2019-2025 | |
| Allergan, INC. | $1,877.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,860.00 | 2022 | |
| Genzyme Corporation | $539.85 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $448.00 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $400.78 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $380.47 | 2022-2025 | Dupixent |
| Pfizer INC. | $346.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.62 | 2019-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $268.03 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $207.10 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $167.45 | 2023-2024 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $157.43 | 2019-2023 | Linzess |
| Ardelyx, INC. | $144.58 | 2023-2025 | Ibsrela |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $142.15 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $137.11 | 2019-2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $124.58 | 2019 | |
| Stryker Corporation | $116.70 | 2024 | N/A, Pedi-Pom |
| Intercept Pharmaceuticals, INC. | $113.48 | 2019-2024 | Ocaliva |
| Novo Nordisk INC | $93.90 | 2025 | |
| Qol Medical, LLC | $91.03 | 2019-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $73.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $67.42 | 2021-2024 | |
| Covidien LP | $67.29 | 2020 | |
| Nevro Corp. | $66.79 | 2021 | |
| Daiichi Sankyo INC. | $58.10 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $54.73 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $53.25 | 2019-2020 | |
| Lilly USA, LLC | $42.90 | 2024 | Omvoh |
| Ucb, INC. | $40.47 | 2019-2020 | |
| Ekos Corporation | $36.42 | 2019 | |
| Concordia Pharmaceuticals INC. | $28.46 | 2019 | |
| Redhill Biopharma INC. | $25.51 | 2022 | |
| Orphalan INC | $21.73 | 2025 | Cuvrior |
| Dentsply Ih Ab | $20.76 | 2024 | Lofric |
| Alexion Pharmaceuticals, INC. | $20.33 | 2019 | |
| Medtronic, INC. | $19.38 | 2025 | Interstim |
| Shionogi INC | $16.85 | 2019 | |
| Celltrion USA INC. | $16.07 | 2024 | Zymfentra |
| Intra-Sana Laboratories | $13.87 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.